10 posts tagged with "AI / ML"

Weekly Intelligence · Week 12 · 24 July 2026 · Issue #012​

The strict 7-day window (17–24 July) stayed quiet for the second week running, so this issue again runs on the catch-up track — but the three reviews it surfaces line up on a subject the newsletter has not yet covered directly: not detecting a first episode, but predicting relapse and deterioration in people already diagnosed. Two independent 2026 reviews map that frontier and reach the same modest numbers; a third, broader scoping review maps the LLM landscape around it.

---

Executive Summary​

For the second consecutive week, no new wearable, speech, multimodal, facial-CV, NLP, or digital-phenotyping primary detection result — and no new regulation clearing the bar — landed inside the strict 7-day window (17–24 July). The freshest industry signal, a NeuroLexIQ–Canary Speech voice-intake partnership announced 15 July, falls just outside the window and outside the backfill track's high-leverage-type gate, so it is logged rather than padded in. Instead this issue leans on three catch-up reviews that, read together, move the newsletter's measurement-discipline thesis onto a new axis. Since Issue #008 the through-line has been about detection — external validation, single-marker insufficiency, unstable leaderboards, implementation and measurement heterogeneity. The three reviews here are about the harder, more clinically valuable task the field is now turning to: predicting relapse and deterioration in people already diagnosed. First, a BMC Psychiatry systematic review (Dormechele et al., May 2026) of passive-sensing approaches to relapse prediction across psychiatric disorders — prospective and retrospective observational studies using passively collected smartphone and wearable data, searched to January 2026, whose verdict is that behavioral digital-phenotype shifts are plausible early-warning signals but the evidence base is not yet dependable. Second, a JMIR Mental Health scoping review (Ghelfi et al., 16 June 2026) narrowing to psychosis relapse, which reports AI-model AUCs spanning a modest 0.63–0.78 and concludes that personalized, individual-level modeling shows promise but needs far larger samples and newer methods before clinical use. Third, a JMIR Mental Health scoping review (Jin et al., 5 May 2025) of 95 studies applying large language models across mental health — 67 of them (71%) on screening and detection — whose bottom line is that despite explosive growth the field remains "nascent and exploratory." The honest read: the in-window frontier was static again, but the catch-up shelf shows the field's ambitions climbing from detection toward prediction — and carrying the same generalization and sample-size problems up the ladder with it.

---

Key Metrics​

Metric	Value	Source
Psychosis-relapse AI scoping review: reported model AUC range	0.63–0.78	Ghelfi et al. · JMIR Ment Health · 16 Jun 2026
LLM-in-mental-health scoping review: studies / screening-detection share	95 / 67 (71%)	Jin et al. · JMIR Ment Health · 5 May 2025
Relapse-prediction systematic review: search window / data modality	to Jan 2026 / passive smartphone + wearable	Dormechele et al. · BMC Psychiatry · May 2026

---

Wearable Biosensors & Digital Phenotyping​

A systematic review moves the goalpost from detection to relapse — and finds the evidence thin​

Wisdom Dormechele, Isaac Yeboah Addo, Caleb Boadi, and colleagues published a systematic review in BMC Psychiatry of passive-sensing approaches to predicting relapse in psychiatric disorders — a deliberate step past the detection-and-screening question this newsletter has tracked all quarter. Searching PubMed, PsycINFO, and IEEE Xplore for studies through January 2026, the review gathered prospective and retrospective observational studies that used passively collected smartphone or wearable data to forecast relapse or clinical deterioration in people with a diagnosed disorder, and that reported quantitative model performance. The framing is the field's most clinically valuable premise: because behavioral digital-phenotype shifts — in mobility, sleep, communication, and social rhythm — may register before a person notices a downturn, passive monitoring opens a window for timely, preventive intervention rather than after-the-fact diagnosis. The review's sober contribution is that this premise is still mostly a promissory note: the underlying studies are observational, heterogeneous in devices and outcome definitions, and small, which keeps relapse prediction short of the reliability routine care would demand. For this newsletter the paper is the natural next chapter after the detection audits of Issues #008–#011: the same passive-sensing apparatus is now being pointed at a harder target, and the same constraints — sample size, heterogeneity, un-validated models — follow it there. Predicting a relapse three days out is a far more useful clinical act than scoring a cross-sectional screen, which is precisely why the gap between the promise and the evidence matters more here, not less.

Source: Dormechele W, Addo IY, Boadi C, et al. · BMC Psychiatry · May 2026 · 10.1186/s12888-026-08157-z

📅 Catch-up — published May 2026, outside the weekly window

---

AI/ML for Mental Health Detection​

A psychosis-relapse scoping review puts a number on it: AI AUCs of 0.63–0.78​

Luca Ghelfi, John Healy, Federico Piacenza, and a large multi-site author group — spanning Irish, Dutch, Norwegian, Turkish, Swiss, and Spanish centers and ending with senior authors Mary Cannon and John Lyne — published a scoping review in JMIR Mental Health narrowing the relapse question to its most-studied condition: psychosis. Searching PubMed, PsycINFO, and Embase from inception to January 2026 for any method with an AI component used to detect psychotic relapse, the review's headline finding is a quantitative one this newsletter can carry forward: across the studies that reported it, AI-model discrimination landed at a modest AUC of 0.63–0.78 — meaningfully better than chance, but well short of the 0.9-plus figures that decorate in-sample detection papers, and a useful reality check on how much harder prediction is than classification. The authors report that passive digital-phenotyping research on psychosis relapse has genuinely progressed and that personalized, individual-level modeling — learning each patient's own behavioral baseline rather than a population average — is the most promising direction, but that the field's studies still need substantially larger participant numbers and should begin incorporating newer methods, including large language models, before the approach is clinic-ready. Read against the Dormechele systematic review above, the two form an unusually clean convergence: one review synthesizes relapse prediction broadly and finds the evidence thin; the other zooms into psychosis and attaches the actual number — 0.63–0.78 — to why. The AUC range and the "needs larger samples" caveat belong in the same sentence, and together they place relapse prediction exactly where detection sat in Issue #008: a real, personalized signal whose generalization is not yet earned.

Source: Ghelfi L, Healy J, Piacenza F, et al. · JMIR Mental Health · 16 June 2026 · 10.2196/92192

📅 Catch-up — published 16 June 2026, outside the weekly window

---

NLP & Large Language Models​

A 95-study scoping review: LLMs are everywhere in mental health, and the field is still "nascent"​

Yu Jin, Jiayi Liu, Pan Li, and colleagues published a scoping review in JMIR Mental Health mapping the full landscape of large-language-model applications across mental health — the breadth-map counterpart to the depth audits this newsletter has run on LLM safety (MHSafeEval, Issue #011) and LLM benchmarks (Ishikawa & Duke, Issue #009). Across 95 included studies, the authors sorted the work into three uses: screening or detection of mental disorders, by far the largest at 67 of 95 (71%); supporting clinical treatment and intervention (31/95, 33%); and assisting mental-health counseling and education (11/95, 12%). The through-line is that the application surface has already sprawled far ahead of the evidence: the review's own summary judgment is that despite the rapid growth and diversity of LLM use, the field remains "nascent and exploratory," dominated by short-horizon, single-session, small-sample evaluations rather than the longitudinal, externally-validated studies clinical adoption would require. For this newsletter the value is contextual — it quantifies just how top-heavy the field is toward detection (the same 71% skew the newsletter keeps encountering) and frames why the safety and benchmark audits of the last two issues matter: a technology this widely applied and this thinly evaluated is precisely the kind that needs disciplined measurement before it touches care. It also sharpens Ghelfi et al.'s prescription above — "incorporate large language models" — with a caution: the LLM layer the relapse field is being urged to adopt is itself, on this review's own reading, not yet a mature instrument.

Source: Jin Y, Liu J, Li P, et al. · JMIR Mental Health · 5 May 2025 · 10.2196/69284

📅 Catch-up — published 5 May 2025, outside the weekly window

---

Forward Outlook​

• Near-term: The two relapse reviews now travel as a pair — Dormechele et al.'s "promising but thin" synthesis and Ghelfi et al.'s concrete AUC 0.63–0.78 for psychosis — and together they give a reviewer a citable anchor for any claim that passive sensing can forecast deterioration. The next result worth flagging is the first relapse-prediction model reporting prospective, externally validated, individual-level performance at a stable AUC, rather than a retrospective in-cohort figure — the same artifact the detection track has been waiting on, now one rung harder.
• Mid-term: Both reviews point at personalization — modeling each patient's own behavioral baseline — as the direction of travel, and at larger, longer cohorts as the missing ingredient. If that holds, the deployment shape for relapse prediction converges on the same triage-grade, human-in-the-loop use the detection literature (Issues #009–#010) and the governance track (WHA79, Issue #007) have been circling: an early-warning nudge routed to a clinician, not an autonomous alarm. Ghelfi et al.'s call to fold in LLMs, read against Jin et al.'s "nascent and exploratory" verdict, suggests the field will graft an immature instrument onto an immature task — worth watching closely.
• Long-term: With this issue the newsletter's binding-constraint thesis extends from detection to prediction: across first-episode screening (Issues #008–#011) and now relapse forecasting, the limiting factor is not model capacity but the trustworthiness of the evidence — sample size, external validation, and prospective design. Accuracy and ambition will keep rising; whether the reviews, benchmarks, and safety evaluations measuring them are disciplined enough to believe is still the open question, and moving up from detecting illness to predicting its return raises the stakes on that question rather than settling it.

---

Sources used: 3 (0 in-window · 3 catch-up) · Week 12 · Next issue: 31 July 2026

Weekly Intelligence · Week 11 · 17 July 2026 · Issue #011​

After last week's brief in-window pair, the strict 7-day window went quiet again (10–17 July), so this issue runs on the catch-up track — three 2025–2026 audits that, read together, extend the newsletter's measurement-discipline thesis across three modalities at once: speech, wearable passive sensing, and large-language-model safety. Each reports strong headline numbers and the same load-bearing caveat underneath them.

---

Executive Summary​

For the first time since Issue #010's two in-window digital-phenotyping papers, no new wearable, speech, multimodal, facial-CV, NLP, or digital-phenotyping primary detection result — and no new regulation or industry development — cleared the strict 7-day window (10–17 July). The strongest in-window candidate that surfaced, a Psychiatry Research general-population digital-phenotyping study (Sameh et al.), is a primary detection model published 25 May and so falls outside both the window and the backfill track's high-leverage-type gate; it is logged as deferred rather than padded in. Rather than stretch the issue, this week leans on the catch-up shelf, which happens to hold three results that line up into a single argument about measurement discipline — and, unusually, they make it from three different modalities. First, a JMIR Mental Health systematic review and meta-analysis (Maran et al., 22 Oct 2025) of 105 automatic-speech-analysis depression studies, whose pooled accuracy spans a wide 0.66–0.81 with I² heterogeneity of 94–99% and 47.6% of studies at high risk of bias — and whose verdict is that speech analysis "should be considered a complementary method," not a standalone diagnostic. Second, a JMIR scoping review (Shen et al., 14 Aug 2025) of 42 passive-sensing studies in clinically diagnosed populations, which quantifies the field's small-sample problem directly — a median of 60.5 participants, external validation in just 1 of 42 studies (2%), and anonymization addressed in only 6 of 42 (14%). Third, MHSafeEval (arXiv, 20 Apr 2026, preprint), a role-aware safety benchmark showing that the multi-turn, cumulative failure modes of LLM mental-health counselors are "systematically missed by existing static benchmarks." The through-line the newsletter has tracked since Issue #008 — impressive aggregate accuracy, unproven generalization — now has a fourth face: the very instruments used to measure safety and performance are themselves too coarse to trust. The honest read: the in-window frontier was static again, but the catch-up track keeps sharpening the same point from new angles.

---

Key Metrics​

Metric	Value	Source
Speech-analysis depression meta: studies / pooled accuracy range / high-bias share	105 / 0.66–0.81 / 47.6%	Maran et al. · JMIR Ment Health · 22 Oct 2025
Passive-sensing scoping review: studies / median participants / external-validation rate	42 / 60.5 / 1 of 42 (2%)	Shen et al. · JMIR · 14 Aug 2025
LLM safety benchmark: failure modes missed by static tests	role-dependent, cumulative, multi-turn	MHSafeEval · arXiv · 20 Apr 2026

---

Speech & Vocal Biomarkers​

A 105-study meta-analysis: speech depression detection is "complementary," not diagnostic​

Patricia Laura Maran, María Dolores Braquehais, Alexandra Vlaic, and colleagues published a systematic review and meta-analysis in JMIR Mental Health synthesizing 105 studies of automatic speech analysis (ASA) for detecting depression, drawn from eight databases across January 2013 to April 2025 and pooled with a three-level meta-analysis. The headline numbers look strong at the top of their range — pooled highest accuracy 0.81 (95% CI 0.79–0.83), sensitivity 0.84, specificity 0.83 — but the review's contribution is the spread and the caveats beneath it, not the ceiling. The pooled lowest estimates fall to accuracy 0.66, sensitivity 0.63, and specificity 0.60, and the heterogeneity is extreme: I² between 94% and 99%, driven by divergent populations, feature sets, and dataset characteristics, with Teager-Energy-Operator features and deep neural networks the best-performing configurations. Nearly half the corpus — 47.6% — carried a high risk of bias in at least one domain, most often insufficient preprocessing documentation and inadequate sample sizes. The authors' conclusion is deliberately deflationary: ASA "should be considered a complementary method" rather than a standalone diagnostic, and the field needs more high-quality, peer-reviewed work before clinical use. For this newsletter the meta-analysis is the speech-modality complement to the audits logged in Issues #008–#010: where Lee et al. (Issue #009) found no single wearable biomarker is sufficient and Alam et al. (Issue #010) found digital-phenotyping implementation too heterogeneous to reproduce, this shows the speech literature carries the same signature — a real signal, a believable top-line number, and a variance structure wide enough that the pooled figure is a summary of disagreement rather than a stable estimate. It also retro-frames the tidy 23-feature parsimony story from Lin et al. (Issue #010): parsimony is exactly the discipline a 94–99% I² field is missing.

Source: Maran PL, Braquehais MD, Vlaic A, et al. · JMIR Mental Health · 22 Oct 2025 · 10.2196/67802

📅 Catch-up — published 22 October 2025, outside the weekly window

---

Wearable Biosensors & Digital Phenotyping​

A 42-study scoping review puts a number on the small-sample problem: median n = 60.5​

ShiYing Shen, Wenhao Qi, Jianwen Zeng, and colleagues published a scoping review in the Journal of Medical Internet Research of 42 peer-reviewed studies using passive sensing from wearables or smartphones with machine learning to monitor clinically diagnosed mental disorders, searched across seven databases from January 2015 to February 2025. The studies were mostly cohort designs (23/42, 55%), concentrated on depression (55%) and anxiety (21%), and leaned on wrist-worn devices (76%) collecting heart rate (67%), movement index (60%), and step count (40%). What makes the review worth logging is that it quantifies the constraints this newsletter has argued qualitatively: the median sample was just 60.5 participants (IQR 54–99), 76% of studies used a single device, 45% monitored for under seven days, external validation appeared in only 1 of 42 studies (2%), and just 14% addressed anonymization. Despite those limits, top-line accuracy again looks excellent — a CNN-LSTM model reached 92.16% for anxiety detection — which is precisely the pattern the audit track keeps surfacing: high in-sample numbers atop thin, un-validated, privacy-light foundations. The authors' prescription echoes the field's emerging consensus — standardized protocols, larger longitudinal studies (≥3 months), explainable models, multimodal fusion, and real data-privacy frameworks. Read against the Alam systematic review from Issue #010, this is the sharper, more numeric cut of the same finding: Alam named the heterogeneity, Shen et al. put the median sample size and the 2% external-validation rate on the table. The 92% anxiety accuracy and the 2% external validation belong in the same sentence — the first is why the field is excited and the second is why the excitement is not yet earned.

Source: Shen S, Qi W, Zeng J, et al. · Journal of Medical Internet Research · 14 Aug 2025 · 10.2196/77066

📅 Catch-up — published 14 August 2025, outside the weekly window

---

AI/ML & Safety Benchmarks​

MHSafeEval: static safety benchmarks miss the multi-turn failures that actually harm​

A team introduced MHSafeEval, a role-aware framework for evaluating mental-health safety in large language models, built around a taxonomy (R-MHSafe) that characterizes clinically significant harm by the interactional role an AI counselor slips into — perpetrator, instigator, facilitator, or enabler — crossed with clinically grounded harm categories. Rather than score isolated single-turn prompts, the framework formulates safety assessment as trajectory-level discovery: it iteratively generates, evaluates, and refines client–counselor interactions through naturalistic adversarial multi-turn attacks, retains high-harm exchanges in a structured Harm Archive, and uses an LLM clinical safety judge to give graded severity feedback while steering toward under-explored failure regions. The load-bearing result is that this surfaces "substantial role-dependent and cumulative safety failures that are systematically missed by existing static benchmarks," and materially improves failure-mode coverage. For this newsletter the paper is the safety-layer counterpart to the Ishikawa & Duke benchmark audit from Issue #009: where that work showed detection leaderboards are unstable across reseeding and external transfer, this shows safety leaderboards are incomplete along a different axis — harm that only emerges across a conversation, not in any single turn, and that depends on the role the model drifts into. It sharpens the WHA79 "warm handoff, not a disclaimer" standard tracked since Issue #007 and the RAG suicide-risk stratifier from Issue #008 into a measurement question: a system that passes a static safety screen can still fail cumulatively in deployment, so a static pass is weak evidence of a safe counselor. It is a preprint, and its harm judgments themselves lean on an LLM judge — a dependency worth watching — but it lands squarely on the through-line that the field's yardsticks, for performance and now for safety, are less firm than the headline pass-rates imply.

Source: MHSafeEval: Role-Aware Interaction-Level Evaluation of Mental Health Safety in Large Language Models · arXiv preprint · 20 Apr 2026 · arXiv:2604.17730

⚠️ Preprint — not yet peer reviewed 📅 Catch-up — published 20 April 2026, outside the weekly window

---

Forward Outlook​

• Near-term: Three catch-up figures now travel as a set — the ASA meta-analysis's 94–99% I², the passive-sensing review's 2% external-validation rate, and MHSafeEval's "static benchmarks miss cumulative harm." Each is a citable line a reviewer can attach to a single-cohort claim, whether the modality is voice, wrist sensor, or chatbot. The next result worth flagging is the first detector or counselor to report stable, externally-validated, multi-turn-tested performance rather than a headline in-sample number — the artifact the field keeps asking for and rarely producing.
• Mid-term: The Maran "complementary, not standalone" verdict and the Shen "median n = 60.5, ≥3-month studies needed" prescription point the same way as the Issue #009–#010 arc: passive and vocal signals earn their keep as adjuncts routed into human care, not as autonomous screeners. If that framing holds across speech, wearables, and LLM counseling at once, the deployment shape converges on triage-grade, human-in-the-loop use — the same destination the governance track (WHA79, Issue #007) has been pressing from the policy side.
• Long-term: With a fourth consecutive theme — external validation (Issue #008), single-marker insufficiency and unstable benchmarks (Issue #009), implementation heterogeneity (Issue #010), and now measurement coarseness across modalities and safety (Issue #011) — the field's binding constraint looks less like model capacity and more like the trustworthiness of its own instruments. Accuracy and fluency will keep rising; whether the meta-analyses, scoping reviews, and safety benchmarks measuring them are disciplined enough to believe is the open question, and no new architecture closes it — only bigger samples, external validation, standardized reporting, and multi-turn safety evaluation do.

---

Sources used: 3 (0 in-window · 3 catch-up) · Week 11 · Next issue: 24 July 2026

Weekly Intelligence · Week 9 · 3 July 2026 · Issue #009​

A fourth consecutive quiet in-window week, so this issue runs on the catch-up track — three 2026 audits of the wearable and physiological-biomarker literature that, read together, move the newsletter's running thesis one step inward: it is no longer only external validation that is missing, but the internal measurement apparatus — single biomarkers, benchmarks, and leaderboards — that turns out to be shakier than the headline numbers suggest.

---

Executive Summary​

For the fourth week running, no new wearable, speech, multimodal, facial-CV, NLP, or digital-phenotyping primary detection result, and no new regulation or industry development, cleared the strict 7-day window (26 June–3 July). The strongest candidates that surfaced in search were either already covered — a JMIR smartphone digital-phenotyping scoping review (10.2196/84146) and an adolescent digital-phenotyping feasibility study (10.2196/72501), both logged in Issue #001 — or a wrist-worn anxiety digital-biomarker meta-analysis (10.2196/73812) already in the registry from Issue #001. Rather than pad the issue, this week leans on the backfill track, surfacing three peer-reviewed or preprinted 2026 results that are genuinely new to this newsletter and that happen to line up into a single argument about measurement discipline. First, a Journal of Medical Internet Research systematic review and meta-analysis (Lee et al., 2 April) of 132 depression digital-biomarker studies — the largest synthesis the newsletter has logged — whose load-bearing conclusion is that no single digital biomarker sufficiently captures depression, and whose pooled effects (sleep-onset latency +4.75 min, time-in-bed +31.8 min, physical-activity SMD −0.71) are real but individually modest. Second, an npj Digital Medicine 10-month wearable study (Matias et al., 14 January) of 82 healthy adults across 21 cognitive and mental-health outcomes, whose authors explicitly state their passively-sensed models are "not intended or evaluated as diagnostic tools" — a rare self-imposed ceiling that names the population-vs-clinical gap directly. Third, a five-dataset benchmark audit (Ishikawa & Duke, 13 May, preprint) showing that the leaderboards ranking clinical-interview depression detectors are unstable — the cross-validation winner ranked 20th on the official test, and the apparent overall winner held rank-1 in only 32.3% of bootstraps. The honest read: the measurement frontier was static in-window for a fourth week, but the catch-up shelf holds three results that, together, sharpen Issue #008's external-validation thesis into a broader audit — the field's internal yardsticks are less firm than the sensitivity figures imply.

---

Key Metrics​

Metric	Value	Source
Depression digital-biomarker synthesis: studies / participants (meta-analytic subset)	132 / 57,852 (22 / 6,947)	Lee et al. · JMIR · 2 Apr 2026
Pooled depression effects: sleep-onset latency / time in bed / activity SMD	+4.75 min / +31.8 min / −0.71	Lee et al. · JMIR · 2 Apr 2026
Benchmark instability: CV winner's rank on official test / winner's rank-1 rate across bootstraps	20th / 32.3%	Ishikawa & Duke · arXiv · 13 May 2026

---

Wearable Biosensors & Digital Biomarkers​

A 132-study meta-analysis: no single digital biomarker is enough for depression​

A team led by Hyeongsuk Lee, Seung-Gul Kang, and SeonHeui Lee published a systematic review with meta-analysis in the Journal of Medical Internet Research synthesizing 132 studies (57,852 participants) of digital biomarkers for depression, with a quantitative meta-analysis over 22 of them (6,947 participants) drawing on sleep, physical-activity, cardiac, speech, GPS, smartphone, and circadian signals. The pooled effects are directionally consistent with the clinical picture but individually modest: people with depression showed a sleep-onset latency roughly 4.75 minutes longer (95% CI 2.46–7.04), time in bed about 31.8 minutes longer (95% CI 18.22–45.39), and significantly reduced physical-activity counts (standardized mean difference −0.71). The review's load-bearing contribution is not any single effect size but its explicit conclusion that "no single digital biomarker sufficiently captures depression-related changes," and its recommendation of personalized, multimodal approaches integrating physiological, behavioral, and contextual signals. That is the wearable-side complement to the multimodal-MDD review this newsletter covered last week (Crema et al., Issue #008), which reached the same destination from the fusion-model side — and it retro-frames the impressive single-modality numbers the newsletter has logged, including the wearable-AI depression meta-analysis noted in Issue #006 (sensitivity 0.89, specificity 0.93, AUC 0.96), as aggregate signals that fragment when you ask which individual marker is doing the work. The caution is the familiar heterogeneity one: pooling across sensors, devices, and cohorts inflates apparent coverage while none of the constituent markers is individually strong enough to screen on its own.

Source: Lee H, Kang S-G, Lee S · Journal of Medical Internet Research · 2 Apr 2026 · 10.2196/76432

📅 Catch-up — published 2 April 2026, outside the weekly window

---

A 10-month wearable study names its own ceiling: population-level, "not diagnostic"​

Igor Matias, Maximilian Haas, Eric J. Daza, Matthias Kliegel, and Katarzyna Wac published a longitudinal npj Digital Medicine study passively monitoring 82 healthy adults for 10 months with consumer wearables, predicting 21 cognitive and mental-health outcomes — including anxiety and depression via the Hospital Anxiety and Depression Scale, plus stress, affect, and hostility. Reported prediction error rates ran as low as 3.22%, with self-reported outcomes more predictable than performance-based measures, and — the methodologically interesting split — environmental factors (weather, air pollutants) explained differences between individuals while physiological rhythms captured within-person change over time. The finding that matters for this newsletter is the authors' own framing: their models "quantify population-level variability" and are "not intended or evaluated as diagnostic tools." That is a rare, self-imposed statement of exactly the ceiling the newsletter has argued around since Issue #002 — a passively-sensed signal that tracks aggregate variation is not the same object as a clinical screener for a diagnosed condition, and conflating the two is how in-sample accuracy gets over-read. Read against the Lee meta-analysis above, the two form a pincer: the meta-analysis says no single marker is diagnostic, and this study says even a well-instrumented multi-sensor pipeline, honestly reported, is population-level rather than clinical. The between- vs within-person decomposition is also a useful design lesson for the digital-phenotyping pipelines tracked since Issue #001 — a model that looks predictive across a cohort may be leaning on environment, not on the individual's changing physiology.

Source: Matias I, Haas M, Daza EJ, Kliegel M, Wac K · npj Digital Medicine · 14 Jan 2026 · 10.1038/s41746-026-02340-y

📅 Catch-up — published 14 January 2026, outside the weekly window

---

AI/ML & Benchmarks​

A five-dataset audit finds the depression-detection leaderboards are unstable​

Takehiro Ishikawa and Jon Duke released a multi-probe audit of clinical-interview depression detection benchmarks, examining evaluation practice across five widely-used datasets (DAIC/E-DAIC, CMDC, ANDROIDS, MODMA, PDCH) through four investigation methods. The results are a direct challenge to how the field reads its own leaderboards. Development-side cross-validation and official-test rankings aligned only moderately: the best cross-validation model ranked 20th on the official test, while the official winner ranked 41st by cross-validation, with zero overlap in the top-3 between the two views. Rankings were also unstable across random seeds — the apparent winner held rank-1 in only 32.3% of subject bootstraps — and strong in-domain baselines degraded sharply on zero-shot transfer to external corpora. A modality-specific bias compounds it: audio models showed minimal sensitivity to symptom density, while text models gained sharply on symptom-dense content, suggesting text detectors may be overfitting to superficial lexical markers rather than learning depression. For this newsletter the audit is the measurement-layer counterpart to Issue #008's external-validation number (84.9% → 32% specificity out-of-sample): where Crema et al. showed models fail to generalize, this shows the very rankings used to pick the "best" model are unstable, so a leaderboard position is weak evidence a detector is actually better. It is a preprint and its own scope is bounded to five corpora, but it lands squarely on the through-line — aggregate benchmark performance looks orderly and the ordering does not survive contact with reseeding or an external set.

Source: Ishikawa T, Duke J · arXiv preprint · 13 May 2026 · arXiv:2605.23977

⚠️ Preprint — not yet peer reviewed 📅 Catch-up — published 13 May 2026, outside the weekly window

---

Forward Outlook​

• Near-term: The Lee "no single biomarker" verdict and the Ishikawa–Duke ranking instability are two citable figures that should now travel together — the first says don't screen on one marker, the second says don't trust a leaderboard to tell you which model does it best. Expect both to be leaned on by reviewers and the FDA digital-advisers track (Issue #006), and the next result worth flagging is the first depression detector reporting stable cross-seed ranking and external validation, rather than a single-split headline number.
• Mid-term: Matias et al.'s self-imposed "not diagnostic" ceiling and the Lee call for personalized multimodal approaches point the same way as the "silent patient" and non-disclosure threads (Issues #005, #008): passive wearable sensing earns its keep as a population-level, complementary signal, not a stand-alone screener. If that framing holds, the deployment case for wearables shifts from "detect the disorder" toward "flag population-level change and route to a clinician," which is the same triage-grade shape the governance track (WHA79, Issue #007) has been pressing.
• Long-term: Three independent 2026 audits converging on the same message — single markers are insufficient, passive sensing is population-level, and benchmarks are unstable — suggests the field's binding constraint is quietly migrating from model capacity to measurement discipline. The detection numbers will keep rising; whether the yardsticks measuring them are trustworthy is now the open question, and no new architecture closes it — only better benchmarks, external validation, and honest scope statements do.

---

Sources used: 3 · Week 9 · Next issue: 10 July 2026

Weekly Intelligence · Week 8 · 26 June 2026 · Issue #008​

A third consecutive quiet in-window week, so this issue runs on the catch-up track — three peer-reviewed results that, read together, describe the same fault line: detection works in the lab, then degrades the moment it meets a real, often non-disclosing patient.

---

Executive Summary​

For the third week running, no new wearable, speech, multimodal, facial-CV, NLP, or digital-phenotyping primary detection result, and no new regulation or industry development, cleared the strict 7-day window (19–26 June). Rather than pad the issue, this week leans on the backfill track, surfacing three peer-reviewed results from earlier in 2026 that are genuinely new to this newsletter and that happen to line up into a single argument. First, a Frontiers in Psychiatry prospective diagnostic study (Zhu et al., 1 April) of an AI visual-psychophysiology screener — facial/head-neck micro-vibration analysis — that lifted depression-screening sensitivity to 95.9% and, crucially, caught "silent" patients with alexithymia or somatization whom self-report scales missed: a direct answer to the 63% non-disclosure ceiling measured in Issue #005. Second, a Frontiers in Digital Health review with systematic search (Crema et al., 17 April) of 40 multimodal-MDD systems, whose load-bearing finding is the field's systematic absence of external validation — one model fell from 84.9% training accuracy to 32% specificity on independent data — quantifying the lab-to-clinic gap the newsletter has tracked qualitatively since Issue #002. Third, a BMC Psychiatry benchmark (Xie et al., 31 March) showing retrieval-augmented LLMs reach F1 0.91 for depression detection and 0.95 for suicide-risk stratification on real physician–patient dialogues — the strongest NLP detection numbers we have logged, and ones that route directly into the "warm handoff to a trained person" standard from Issue #007. The honest read: the measurement frontier was static in-window again, but the catch-up shelf holds three results that sharpen, rather than merely repeat, the newsletter's running thesis.

---

Key Metrics​

Metric	Value	Source
Visual-AI depression-screening sensitivity (vs. SDS 83.6%; AI+SDS 98.6%)	95.9%	Zhu et al. · Front. Psychiatry · 1 Apr 2026
Multimodal-MDD model: training accuracy → external-test specificity	84.9% → 32%	Crema et al. · Front. Digital Health · 17 Apr 2026
RAG-LLM F1 — depression detection / suicide-risk stratification	0.91 / 0.95	Xie et al. · BMC Psychiatry · 31 Mar 2026

---

Facial Expression & Computer Vision​

A visual-psychophysiology screener catches the "silent" patients self-report misses​

A team led by Zhu and colleagues at Shenzhen Luohu Maternal and Child Health Hospital ran a single-center prospective diagnostic-accuracy study (February–September 2025, 98 outpatients who completed all assessments, 76.5% of them adolescents aged 12–18) comparing an AI visual psychophysiological analysis platform — which reads facial and head-neck micro-vibration signals from a short video — against the standard self-report scales (SDS for depression, SAS for anxiety). For depression, the AI tool reached 95.9% sensitivity versus 83.6% for the SDS, and a combined "AI broad-screen + scale-refine" model hit 98.6% sensitivity (F1 0.847); for anxiety the combined model improved recall by roughly 50% over the SAS alone (F1 0.590). The finding that matters for this newsletter is not the headline sensitivity but who the AI caught: the platform was "particularly effective at identifying silent patients with alexithymia or somatization features" that self-report scales systematically missed. That is a direct mechanistic counterpoint to the demand-side ceiling Issue #005 measured — the 63% of young chatbot users who disclose their distress to no one. A passively-observed visual signal does not depend on the patient being willing or able to report how they feel, which is precisely the cohort that non-disclosure renders invisible to questionnaire-based intake. The caveats are the familiar ones: a single site, a modest and adolescent-skewed sample, and no external validation — the same limitation the next item makes the week's theme.

Source: Zhu H, You H, Nie Y, et al. · Frontiers in Psychiatry (Vol. 17) · 1 Apr 2026 · 10.3389/fpsyt.2026.1729303

📅 Catch-up — published 1 April 2026, outside the weekly window

---

AI/ML & Multimodal Systems​

A 40-study review pins the number on multimodal MDD's external-validation gap​

Crema and colleagues published a review with systematic search design in Frontiers in Digital Health covering 40 multimodal AI systems for major depressive disorder (published after 2015; 30 clinical-application studies and 10 translational). Reported diagnostic accuracies cluster between 65% and 85%, with MRI-based models reaching AUCs of 0.7–0.9 and the more scalable audio-visual biomarker models landing at AUCs of 0.6–0.8. The review's load-bearing contribution is a methodological indictment rather than a performance ceiling: a systematic absence of external validation across most studies, with performance "often degrading significantly on independent test sets" — the authors cite one model that fell from 84.9% training accuracy to 32% specificity when tested out-of-sample. That single figure is the most legible quantification yet of the lab-to-clinic gap this newsletter has tracked qualitatively since Sohn et al.'s finding that 23 of 39 trials ran without safety monitoring (Issue #002) and through the FDA advisory committee's call for stronger before-and-after deployment evidence. It also retro-frames every impressive single-cohort sensitivity number the newsletter has logged — including this issue's own visual-psychophysiology result — as provisional until it survives an independent dataset. Read with the prior multimodal-screening meta-analyses already noted (pooled AUC ~0.95, Issue #006), the through-line is sharpening: aggregate accuracy looks excellent and generalization remains unproven.

Source: Crema C, De Francesco S, Baronio CM, et al. · Frontiers in Digital Health · 17 Apr 2026 · 10.3389/fdgth.2026.1812241

📅 Catch-up — published 17 April 2026, outside the weekly window

---

NLP and Text-Based Detection​

Retrieval-augmented LLMs hit F1 0.95 on suicide-risk stratification from real dialogues​

A Nanjing Medical University team (Xie, Song, Lu, Fei, et al.) benchmarked retrieval-augmented generation (RAG) large language models for depression screening and suicide-risk stratification in BMC Psychiatry, using real-world physician–patient dialogues (sourced from Haodf.com), a set of 154 standardized patient cases, and negative-control cohorts. Qwen3 + RAG reached an F1 of 0.91 for binary depression detection and 0.95 for suicide-risk stratification on the standard case set (DeepSeek-V3.1 + RAG trailed at F1 0.89–0.90), and RAG lifted suicide-risk F1 by roughly 0.15 over non-RAG baselines. Agreement with clinician labels was high (overall κ = 0.93; diagnostic-class consistency κ = 0.97), and human raters scored model empathy at 4.2–5.0 out of 5. These are the strongest NLP detection numbers the newsletter has logged — but the same generalization caution from the Crema review applies, sharpened by the fact that the benchmark is single-language and built partly on standardized cases rather than fully naturalistic crisis transcripts. What makes the result newsworthy here is the task: suicide-risk stratification is exactly the decision point where Issue #007's WHA79 "warm handoff to a trained person, not a disclaimer" standard binds. A model that can stratify risk at F1 0.95 is only useful if it is wired to route the high-risk tier into a resourced human service — the stratifier is the detector; the handoff is the safety system — which keeps this firmly in triage-grade, human-in-the-loop territory rather than autonomous response.

Source: Xie W, Song X, Lu Z, et al. · BMC Psychiatry (Vol. 26, art. 386) · 31 Mar 2026 · 10.1186/s12888-026-07988-0

📅 Catch-up — published 31 March 2026, outside the weekly window

---

Forward Outlook​

• Near-term: The Crema review's external-validation number (84.9% → 32%) is the citable figure that should now accompany every single-cohort sensitivity claim — including the visual-psychophysiology result in this issue. Expect reviewers and the FDA's digital-advisers track (Issue #006) to lean on it; the next evidence worth flagging is the first of these high-sensitivity screeners to report prospective, external validation rather than in-sample accuracy.
• Mid-term: The visual-psychophysiology "silent patient" finding and the McBain non-disclosure ceiling (Issue #005) point the same direction: passively-observed modalities (facial micro-vibration, voice, digital phenotyping) earn their keep precisely where self-report and chatbot-disclosure fail. If that complementarity holds under external validation, the deployment case shifts from "AI replaces the questionnaire" to "AI sees the cohort the questionnaire can't."
• Long-term: The RAG suicide-risk stratifier crystallizes the field's real frontier — not whether a model can detect risk (F1 0.95 says it increasingly can), but whether there is a resourced, trained human at the receiving end of the handoff, the constraint the WHA79 readout (Issue #007) and the GBD 2023 capacity argument (Issue #003) both named. Detection accuracy is converging; care capacity and validation discipline are the binding limits, and no benchmark closes them alone.

---

Sources used: 3 · Week 8 · Next issue: 3 July 2026

Weekly Intelligence · Week 6 · 12 June 2026 · Issue #006​

The EU AI Act's draft high-risk classification guidelines are in open consultation through 23 June — the first Brussels-side signal material to AI mental-health detection tools, and it layers on top of the Medical Device Regulation rather than replacing it.

---

Executive Summary​

This was a genuinely quiet week for primary detection research and a substantive one on the European regulatory axis. No new wearable, speech, multimodal, or digital-phenotyping primary result cleared the strict 7-day window: the strongest candidate papers that surfaced in search all date earlier — a JMIR Mental Health wearable-AI depression meta-analysis (sensitivity 0.89, specificity 0.93, AUC 0.96) published 10 March 2026, a Nature Mental Health multimodal deep-learning review published 4 May 2026, and an npj Digital Medicine multimodal-screening meta-analysis (pooled AUC 0.95) from 2025 — and are held out as out-of-window. The single firmly-dated, live development this week is regulatory and new to this newsletter: the European Commission's draft guidelines on the classification of high-risk AI systems under the EU AI Act, published 19 May 2026 and now in a public consultation that runs through 23 June 2026. For the first time the EU-side rules are material here — and they matter specifically because most mental-health detection tools are medical devices, so the guidelines stack a high-risk AI-Act layer on top of existing Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) obligations rather than replacing them. This extends the regulatory thread the newsletter has tracked entirely on the US side until now — Utah HB 452 (Issue #001), the Johns Hopkins "800-bill / 3-enacted" state review (Issue #004), and the FDA digital-advisers track — across the Atlantic, and it lands while the comment window is still open.

---

Ethics, Regulation, and Clinical Translation​

EU AI Act: high-risk classification guidelines open for comment — and they reach mental-health detection tools​

On 19 May 2026 the European Commission published three draft documents clarifying how AI systems are classified as high-risk under Article 6 and Annexes I and III of the EU AI Act — one on general classification principles, one on high-risk classification for AI embedded in regulated products (Annex I), and one on the stand-alone high-risk use cases (Annex III). The Commission opened a public consultation on the package that runs through 23 June 2026, with no formal adoption date yet set. The detail that makes this the week's load-bearing development for this newsletter is the treatment of health AI: the Annex I guidance explicitly addresses AI components inside medical devices, and clarifies that AI-Act high-risk obligations will be layered on top of existing Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) requirements rather than substituting for them. Because most behavioral early-detection tools — voice biomarkers, digital-phenotyping pipelines, multimodal screeners — are, or are heading toward being, regulated as medical devices, this is the first concrete signal of how the EU will classify the exact category of system the newsletter tracks. It sits above the AI Act's already-in-force Article 5 prohibitions, which bar manipulative or vulnerability-exploiting systems (including those that foster anxiety, depression, or addictive use, and those targeting children), and ahead of the August 2026 date when the full high-risk obligations become enforceable. The comment window being open this week is the actionable hook: developers and clinicians have until 23 June to shape how detection-grade mental-health AI gets classified in the EU.

Source: European Commission · "Draft Commission guidelines on the classification of high-risk AI systems" · 19 May 2026 · digital-strategy.ec.europa.eu Source: Covington / Inside Privacy · "EU AI Act Update: The European Commission Publishes Draft Guidelines on HRAIs" · May 2026 · insideprivacy.com Source: RAPS · "EU Commission drafts guidelines on classifying high-risk systems under the AI Act" · 2026 · raps.org

---

Forward Outlook​

• Near-term: Expect a cluster of stakeholder submissions before the 23 June deadline, with medical-device and digital-health groups pressing on the MDR/IVDR-plus-AI-Act double-layer — the single most consequential point for anyone shipping a detection-grade tool in the EU. Watch for the first explicit guidance on where a passively-sensing or voice-biomarker screener falls between "high-risk medical device AI" and the lighter-touch categories.
• Mid-term: With full high-risk obligations enforceable from August 2026, the EU layer becomes the mirror image of the US picture the newsletter has tracked — where statute is near-absent (the JHU 800-bill / 3-enacted review, Issue #004) and the FDA has authorized no mental-health generative-AI device to date. The transatlantic divergence — comprehensive-but-heavy in the EU, sparse-but-permissive in the US — will start to shape where vendors launch and validate first.
• Long-term: If detection tools are classified high-risk in the EU and clear MDR/IVDR, the resulting conformity-assessment paper trail could become the de-facto global evidence bar — the regulatory analogue to the model-level safety benchmarks (VERA-MH, Mpathic) the newsletter has argued are functioning as interim governance while statute catches up.

---

Sources used: 3 · Week 6 · Next issue: 19 June 2026

Weekly Intelligence · Week 4 · 30 May 2026 · Issue #004​

Drexel's "bond paradox" pins down when AI-companion use turns harmful, while a national review finds only 3 of ~800 state AI bills became mental-health law.

---

Executive Summary​

This was a quiet week for primary detection research and an instructive one on the demand-and- governance axis. Two firmly-dated developments stand out, and they rhyme. First, a Drexel University team (presented at ACL 2026, preprint online) mined ~4 million Reddit posts down to 5,126 first-person accounts of using AI for mental-health support and surfaced a "bond paradox": task-scoped use (organising thoughts, learning a coping exercise) is overwhelmingly positive, whereas open-ended emotional bonding without a goal correlates with dependence, worsening symptoms, and shame — a behavioral signature, not a content one, which is the kind of signal this newsletter tracks. Second, at a Johns Hopkins "AI for Hope" policy session on 27 May, a Beth Israel Deaconess / Harvard psychiatrist presented a national legislative review finding that of nearly 800 AI-related state bills introduced across all 50 states (Jan 2022–May 2025), only 28 explicitly mention mental health and just 3 were enacted — quantifying the regulatory gap that the Utah HB 452 post-mortem (Issue #001) framed qualitatively. No new wearable, speech, or multimodal primary results cleared the 7-day window this week; several promising papers surfaced in search but date to April or early May and are held out. The honest read: the field's measurement frontier was static this week, but the evidence base on who is using these tools, how, and under what (absent) rules moved meaningfully.

---

Key Metrics​

Metric	Value	Source
Drexel study — Reddit posts screened / analysed	~4M / 5,126	Drexel · ACL 2026 · 28 May 2026
Drexel posts explicitly naming AI risks / limitations	51%	Drexel · ACL 2026 · 28 May 2026
State AI bills (2022–2025) mentioning mental health / enacted	28 of ~800 / 3	JHU "AI for Hope" · 27 May 2026

---

NLP and Text-Based Detection​

Drexel's "bond paradox": when emotional reliance on AI flips from helpful to harmful​

A Drexel University team — lead author Elham Aghakhani with Shadi Rezapour (College of Engineering and Computing) — analysed roughly 4 million Reddit posts across 47 mental-health subreddits, narrowing to 5,126 first-person accounts of using AI chatbots for emotional support, and applied two sociological lenses: a therapist–client rapport framework and a technology-adoption framework. The central finding they label the "bond paradox": when people use AI for a specific, bounded task — organising thoughts, rehearsing a coping skill, drafting what to say to a clinician — the experience is overwhelmingly positive; but when users pursue an open-ended emotional bond or seek endless reassurance without a goal, the dynamic inverts toward emotional dependence, worsening symptoms, and feelings of shame and guilt. Notably, 51% of analysed posts explicitly named risks or limitations, and few users framed AI as a replacement for human care. For this newsletter the contribution is methodological as much as clinical: the harmful signal is a relational-behavioral pattern (goal-less bonding, difficulty disengaging) rather than a single utterance — exactly the long-horizon, breadcrumb-style risk that the Mpathic benchmark (Issue #002) showed deployed models miss. The "bond paradox" gives that failure mode an interpretable, user-side behavioral definition that detection and guardrail systems could in principle target.

Source: Aghakhani E, Rezapour S, et al. · arXiv preprint, presented at ACL 2026 · 28 May 2026 · arXiv:2601.20747 Source: Drexel University / Medical Xpress · 28 May 2026 · medicalxpress.com Source: Neuroscience News · "Study Exposes Risks of Emotional Bonds With AI Chatbots" · 2026 · neurosciencenews.com

⚠️ Preprint — not yet peer reviewed

---

Ethics, Regulation, and Clinical Translation​

National legislative review: 28 of ~800 state AI bills mention mental health, only 3 enacted​

At a Johns Hopkins University "AI for Hope" mental-health-policy session on 27 May 2026, a psychiatrist from Harvard's Beth Israel Deaconess Medical Center presented a national review of state-level legislation, examining nearly 800 AI-related bills introduced across all 50 states between January 2022 and May 2025. Only 28 of those bills explicitly mention mental health, and just 3 were enacted into law — a quantified picture of how far statute lags the now-large consumer behavior it nominally governs (the same session cited that more than 5 million young people aged 12–21 have used AI chatbots for mental-health advice). The finding extends, with hard numbers, the qualitative regulatory thread this newsletter has tracked since the Utah HB 452 post-mortem (Issue #001): HB 452 is not just first, it is nearly alone. The data point is the strongest current denominator for the policy-side gap that mirrors the evidence-side gap (Sohn et al.'s 23-of-39 trials without safety monitoring, Issue #002) and the demand-side gap (the Drexel "bond paradox," this issue). All three describe the same structural lag from different angles — usage and risk are scaling faster than evidence, evaluation, or law.

Source: Johns Hopkins University · "AI for Hope" mental-health-policy session · 27 May 2026 · jhu.edu

---

Forward Outlook​

• Near-term: Expect the Drexel "bond paradox" framing to be picked up quickly as a design target — guardrail and companion-app teams now have a named, user-side behavioral failure mode (goal-less bonding, disengagement difficulty) to instrument against, complementing the utterance-level and multi-turn benchmarks (Verily VMHG, Mpathic, VERA-MH) covered in prior issues. Watch for at least one vendor to claim "bond-paradox-aware" routing within a quarter.
• Mid-term: The 800-bill / 3-enacted figure will become a citation staple in state-legislative testimony and in the Colorado / California / New York efforts flagged in Issue #001. The gap it quantifies strengthens the case for model-level safety benchmarks (VERA-MH, Mpathic) as de-facto governance while statute catches up.
• Long-term: The convergence of three independently-measured gaps — demand-side (bond paradox), evidence-side (thin safety reporting), and policy-side (near-absent statute) — reinforces the triage-grade, human-in-the-loop deployment shape this newsletter has argued toward: detection and routing into clinician care rather than autonomous emotional companionship, which is precisely the configuration the Drexel data suggests is safe versus the one it suggests is harmful.

---

Sources used: 4 · Week 4 · Next issue: 6 June 2026

Weekly Intelligence · Week 3 · 23 May 2026 · Issue #003​

The Lancet's GBD 2023 update lands 1.2B globally with anxiety up 158% since 1990, and Spring Health's VERA-MH crystallises as the open-source safety benchmark The Path used to anchor its $14.3M launch.

---

Executive Summary​

This was an epidemiology- and industry-positioning week. The most consequential signal is The Lancet's Updated trends in the global prevalence and burden of mental disorders, 1990–2023 — a Global Burden of Disease 2023 systematic analysis across 204 countries — putting the worldwide prevalence of mental disorders at ≈1.2 billion in 2023, a 95.5% increase since 1990, with anxiety and depression registering 158% and 131% growth respectively over that window. The 15-to-19 age band is, for the first time in GBD history, the peak-burden cohort. On the industry side, two interlinked announcements on 21 May reframe how mental-health AI products will go to market: Tony-Robbins-co-founded The Path exited stealth with a $14.3M seed (Prime Movers Lab–led) and positioned itself by self-reporting a score of 95 on VERA-MH, the open-source Spring Health / Expert Council evaluation that has emerged this spring as the field's first openly-licensed multi-turn clinical-safety benchmark for mental-health LLMs (distinct from last week's Mpathic clinician-built suite, which is not open-sourced). The week is short on new primary research but long on infrastructure: a population-level prevalence baseline and an evaluation primitive that challengers can now build against.

---

Key Metrics​

Metric	Value	Source
GBD 2023 global mental-disorder prevalence (2023)	1.2 billion	The Lancet · 21 May 2026
GBD 2023 anxiety / MDD growth since 1990	+158% / +131%	The Lancet · 21 May 2026
The Path seed round / claimed VERA-MH score	$14.3M / 95 of 100	TechCrunch · 21 May 2026

---

Epidemiology​

Lancet GBD 2023: global mental-disorder burden reaches 1.2B, peak shifts into the 15–19 cohort​

The Institute for Health Metrics and Evaluation–led Global Burden of Disease 2023 mental- disorder update was published in The Lancet on 21 May 2026 and is the field's first major post-pandemic systematic re-baseline. The analysis covers 12 mental-disorder categories across 204 countries and territories from 1990 to 2023. Headline findings: prevalence reaches ≈1.2 billion globally in 2023, a 95.5% rise since 1990; anxiety disorders grew 158% and major depressive disorder 131% over the same period, jointly the world's two most common mental-health conditions. For the first time in GBD history the peak-burden cohort is the 15-to-19 age band, displacing the previously dominant young-adult window — a structural shift the authors flag as "a more concerning phase of worsening mental disorder burden globally." Female burden is disproportionate across the lifespan. The paper functions as the new denominator the computational-behavioral-detection literature should be sized against: the gap between detection research throughput and the at-risk adolescent population it nominally serves is now larger than any prior GBD wave has reported, and the case for scalable early-detection pipelines (passive, unobtrusive, school-deployable) — rather than clinic-bound assessment — is incrementally strengthened by the demographic shift alone.

Source: GBD 2023 Mental Disorders Collaborators · The Lancet · 21 May 2026 · 10.1016/S0140-6736(26)00519-2 Source: Brenda Goodman · CNN Health · 21 May 2026 · cnn.com

---

AI / ML for Mental Health Detection​

VERA-MH emerges as the first open-source clinician-rubric benchmark a new entrant has scored against​

The Spring Health / Expert Council benchmark Validation of Ethical and Responsible AI in Mental Health (VERA-MH) — first proposed in late 2025 and now in its 60-day Request for Comment phase — is the first openly-licensed multi-turn evaluation rubric for mental-health LLMs and is methodologically distinct from last week's Mpathic clinician-built suite (Issue #002), which is not open-sourced and is held by a single vendor. VERA-MH uses a clinically-developed rubric applied by an LLM-as-judge against synthetic multi-turn role-plays grounded in evidence-based suicide-prevention practice; preliminary validation reports an inter-clinician inter-rater reliability of 0.77 and an LLM-judge–to-clinical-consensus agreement of 0.81. Spring Health's own deployed system scored 82/100. The benchmark's structural contribution this week is not the numbers themselves but the category: a non-vendor, open-source, multi-turn safety evaluation challengers can now publicly score against — a primitive the chatbot field has so far lacked. The release timing is significant: 21 May saw the first third-party product (The Path; see Industry section) anchor a launch on a self-reported VERA-MH score, indicating the benchmark is moving from proposal to industry adoption inside one quarter.

Source: Spring Health · "Spring Health and Expert Council Release VERA-MH, the First Open-Source Evaluation for Validating AI in Mental Health" · 2026 · springhealth.com Source: VERA-MH preprint · arXiv · 2026 · arXiv:2602.05088

⚠️ Preprint — not yet peer reviewed

---

Industry and Product News​

The Path closes $14.3M seed, exits stealth with self-reported VERA-MH score of 95​

The Path, a Tony-Robbins-co-founded AI mental-health platform built by former Calm leadership (data-science / AI head Anson Whitmer and engineering head Tyler Sheaffer), exited stealth on 21 May with a $14.3M seed round led by Prime Movers Lab (where Robbins is a partner). The product offers eleven configurable AI "therapists," is free at launch with a planned $40/month tier, and has handled ≈3.5M messages across ~50,000 users since soft launch. The most relevant detail for this newsletter is positional: The Path is the first stealth-exit product this cycle to anchor its launch communication on a self-reported VERA-MH safety score (95 of 100), with the press release directly contrasting that figure against a "top score of 65 for consumer bots." The release is consequential less for the round size than for the new market entry pattern it codifies: the safety-benchmark-self-report is now a launch-narrative primitive on the same axis as efficacy claims and clinician-endorsement claims, which is the position FDA digital-health advisers and the AMA's April letter to Congress (covered as background in earlier issues) have been pushing for over the last six months. Expect competing entrants and incumbents (Wysa, Woebot, Replika, Character.AI) to publish VERA-MH scores within weeks — and a parallel pattern to emerge for the Mpathic suicide benchmark — as not doing so becomes a negative inference.

Source: Marina Temkin · TechCrunch · 21 May 2026 · techcrunch.com Source: MobiHealthNews · 21 May 2026 · mobihealthnews.com Source: HIT Consultant · 21 May 2026 · hitconsultant.net

---

Forward Outlook​

• Near-term: Watch for Wysa, Woebot, Limbic, Character.AI, and at least one of the frontier-lab providers (Anthropic, OpenAI, Google) to publish VERA-MH scores within 4–6 weeks. The benchmark's RFC period closes during that window, and the first revised version is likely to harden score interpretability before the Mpathic vs. VERA-MH dual-benchmarking pattern settles. Expect a small wave of methodology critiques of VERA-MH's LLM-as-judge step, mirroring the analogous critique cycle that hit medical LLM evaluation in late 2025.
• Mid-term: The GBD 2023 adolescent-peak finding will be cited heavily in funding and policy arguments for school-deployed passive-sensing and digital-phenotyping pipelines (Mindcraft, mindLAMP-schools, Beiwe-schools) over the next 12 months. The IHME data is the strongest current denominator for "the cohort we are nominally trying to detect early." Expect at least one major US or UK national funder to issue an adolescent-cohort-specific digital biomarker RFP citing the GBD figures by year-end.
• Long-term: The combined GBD trajectory (+95.5% prevalence over 33 years, with pandemic-era step changes that have not reverted) and the structural deficit of clinical-workforce capacity make a triage-grade AI screening layer the most plausible high-impact deployment shape — pushing the field's normative target away from autonomous treatment and toward signal-routing into human-clinician care. VERA-MH's design (multi-turn, safety-first, open-source rubric) is well-aligned with that shape; the Mpathic safety benchmark is the parallel commercial-vendor anchor for the same evaluation surface.

---

Sources used: 8 · Week 3 · Next issue: 30 May 2026

Weekly Intelligence · Week 2 · 16 May 2026 · Issue #002​

Mpathic's clinician-built safety benchmark exposes frontier-model blind spots, npj Digital Medicine lands the first dedicated chatbot-management meta-analysis, and bipolar digital phenotyping calls for standardized "digital signatures."

---

Executive Summary​

This was a safety- and evaluation-heavy week. The most consequential release was a new clinician-built mental-health-safety benchmark from Seattle-based Mpathic — 300 multi-turn role plays (10–15 turns) authored by 50 licensed clinicians, run across six frontier models — surfaced on 12 May by Axios and Fortune. The headline result: Anthropic's Claude Sonnet 4.5 led on combined safety + helpfulness on the suicide benchmark, OpenAI's GPT-5.2 stood out for consistently avoiding harmful responses, and every model studied missed subtle and long-horizon risk signals. On the research side, npj Digital Medicine published Sohn et al.'s 39-study meta-analysis of chatbots in the management of depressive and anxiety symptoms (n=7,401 / 7,621) — modest pooled effects (g=0.31 depression, g=0.28 anxiety) and a striking finding that 23 of 39 included trials reported no systematic safety monitoring. SAGE published a bipolar-disorder digital-phenotyping review (Torales et al., 7 May) arguing the field still lacks operational definitions for "digital signatures." Together the week sharpens an emerging frame: the field's bottleneck has shifted from can we measure? to can we measure safely, and at what effect size that survives heterogeneity?

---

Key Metrics​

Metric	Value	Source
Mpathic suicide benchmark — role plays / clinician authors	300 / 50	Axios · Fortune · 12 May 2026
Sohn et al. pooled effect size — depression / anxiety	g = 0.31 / 0.28	npj Digital Medicine 2026
Sohn et al. chatbot trials reporting no systematic safety monitoring	23 / 39	npj Digital Medicine 2026

---

AI / ML for Mental Health Detection​

Mpathic publishes the first clinician-built safety benchmark for frontier mental-health chats​

Seattle-based Mpathic released a new clinician-built evaluation suite for AI safety in mental health conversations. The suicide benchmark comprises 300 multi-turn role plays, each 10–15 turns long, authored by 50 licensed clinicians; an analogous eating-disorder benchmark was run in parallel. Six frontier models were evaluated. Anthropic's Claude Sonnet 4.5 had the highest score across combined safety and helpfulness on the suicide benchmark, while OpenAI's GPT-5.2 was singled out for consistently avoiding harmful responses. The cross-cutting finding is more diagnostic than the leaderboard: every model studied performed well when risk statements were explicit and crystallised, and degraded sharply when risk surfaced through "breadcrumbs" — subtle withdrawal, hopelessness without an explicit ideation statement, or beliefs that escalated over the course of a conversation. The release is methodologically distinctive against last week's Verily Mental Health Guardrail (single-turn classification) and PsychiatryBench (textbook-grounded QA) in that it evaluates sustained conversational reasoning rather than utterance-level classification — the regime in which deployed chatbots actually fail.

Source: Tina Reed · Axios · 12 May 2026 · axios.com Source: Beatrice Nolan · Fortune · 12 May 2026 · fortune.com

---

NLP and Text-Based Detection​

Sohn et al.: 39-study meta-analysis of chatbots in depression and anxiety management — modest effects, thin safety reporting​

A new systematic review and meta-analysis from Sohn, Ha, Park and colleagues in npj Digital Medicine aggregated 39 randomised controlled trials of chatbot interventions targeting depressive and anxiety symptoms: 38 studies (n = 7,401) for depression and 34 (n = 7,621) for anxiety. Pooled effects were statistically significant but modest — Hedges' g = 0.31 (95% CI 0.17–0.46) for depression and g = 0.28 (95% CI 0.05–0.51) for anxiety — versus controls. The geography is concentrated (United States n = 10, China n = 7, Japan n = 4, Hong Kong n = 3), with most studies in non-clinical (n = 15) or sub-clinical (n = 14) rather than clinical populations (n = 10). The authors flag a single critical limitation: 23 of the 39 included trials reported no systematic safety monitoring or adverse-event data. The paper is the first dedicated meta-analytic synthesis specifically of chatbots in symptom management (distinct from prior reviews of chatbot well-being interventions or AI conversational agents in general), and crystallises the gap between efficacy reporting and safety reporting that the Mpathic and Verily benchmarks are now trying to close from the evaluation side.

Source: Sohn JS, Ha BG, Park S, et al. · npj Digital Medicine · 2026 · 10.1038/s41746-026-02566-w

---

Digital Phenotyping​

Torales et al. argue bipolar disorder digital phenotyping still lacks standardized "digital signatures"​

A review by Julio Torales, Marcelo O'Higgins, Iván Barrios and collaborators in the International Journal of Social Psychiatry (SAGE, first published online 7 May 2026) takes stock of passive and active digital phenotyping for bipolar disorder. The review synthesises the literature on sensor streams — sleep, mobility, social rhythm, communication patterns, speech, heart-rate variability — and the platforms (mindLAMP, Beiwe, Fitbit-based studies) that have produced the strongest signals to date. The authors' contribution is mostly conceptual: they argue that the field has accumulated reproducible findings (sleep onset latency variability, mobility variability, mood-symptom precursors) but lacks an operational definition of what a clinically meaningful "digital signature" of bipolar disorder is, what its temporal granularity should be, or how it should be validated against episode transitions. The paper reads as a call for the bipolar community to consolidate around shared signature definitions before another wave of model-development papers fragments the evidence base further.

Source: Torales J, O'Higgins M, Barrios I, et al. · International Journal of Social Psychiatry · 7 May 2026 · 10.1177/00207640261449667

---

Ethics, Regulation, and Clinical Translation​

"AI psychosis" and pre-clinical chatbot adoption crystallise as the dominant mental-health-AI story this week​

A pair of widely-circulated pieces — Beatrice Nolan in Fortune and Tina Reed in Axios, both published 12 May — framed the week's public conversation around the gap between rapidly expanding chatbot use for mental-health support (22% of US adults reported in Axios) and the absence of clinical validation, regulatory clearance, or systematic safety evaluation. Both stories cite the Mpathic findings (above) as primary evidence, alongside the now-canonical examples of chatbots representing themselves as licensed therapists, model sycophancy reinforcing distorted beliefs, and the emerging informal-clinical-vocabulary term "AI psychosis." The Fortune piece in particular positions this week's reporting as the inflection point at which behavioral-health systems — not just regulators — start treating patient chatbot use as a clinical-intake variable. This is the news side of the same arc the Sohn meta-analysis describes from the evidence side.

Source: Beatrice Nolan · Fortune · 12 May 2026 · fortune.com Source: Tina Reed · Axios · 12 May 2026 · axios.com

---

Forward Outlook​

• Near-term: Expect frontier-model providers to publish Mpathic-style scores within weeks; the benchmark is now the most clinician-credible artifact a model lab can score against and the bar for "safety + helpfulness" leaderboards will move from utterance-level to multi-turn role play.
• Mid-term: The Sohn meta-analysis will become the default citation for chatbot effect sizes in policy and payer conversations, and its safety-reporting indictment (23/39) is likely to feed directly into CONSORT-AI-style extensions and into journal editorial requirements for trial registration of safety endpoints in conversational-AI mental-health RCTs.
• Long-term: The Torales digital-signature framing may seed a multi-site bipolar consortium effort akin to what the LAMP Consortium achieved for platform standardisation but at the biomarker-definition layer — a missing primitive without which prospective bipolar digital-phenotyping trials remain difficult to compare.

---

Sources used: 6 · Week 2 · Next issue: 23 May 2026

Weekly Intelligence · Week 1 · 9 May 2026 · Issue #001​

Verily's mental-health guardrail and PsychiatryBench arrive at npj Digital Medicine, an Oura-Ring study links passive measures to next-day panic attacks, and Utah's HB 452 gets its first formal post-mortem.

---

Executive Summary​

The first weekly issue lands in a busy week for npj Digital Medicine: the journal published two purpose-built clinical-AI artifacts — Verily's Mental Health Guardrail (a crisis-detection layer for LLM-mediated conversations) and PsychiatryBench (a 5,188-item multi-task benchmark grounded in psychiatric textbooks) — that together push the field toward shared safety primitives and shared evaluation. On the wearable side, two new outputs reframe the evidence base: a Frontiers in Digital Health study links passive Oura Ring signals to next-day panic attacks in young adults, and a JMIR Mental Health meta-analysis quantifies wearable-AI depression detection at pooled sensitivity 0.89 / specificity 0.93. A npj Digital Medicine commentary by University of Utah and Office of AI Policy authors offers the first peer-reviewed account of how Utah's HB 452 mental- health-chatbot law was scoped and assessed pre-deployment. WBUR's "AI in the doctor's office" series (5–7 May) crystallised the clinical concern that LLM chatbots show empathy but routinely miss safety steps. A measurable financial signal: Tava Health closed a $40M Series C and launched a free AI clinical-scribe + practice-management bundle (Symphony) for behavioral providers.

---

Key Metrics​

Metric	Value	Source
Verily Mental Health Guardrail sensitivity / specificity	0.990 / 0.992	npj Digital Medicine, 2026
Wearable-AI depression detection (pooled sens / spec, 16 studies, n=1,189)	0.89 / 0.93	JMIR Mental Health, 2026
Tava Health Series C raise (May 2026)	$40M	Centana Growth Partners-led

---

AI / ML for Mental Health Detection​

Verily Mental Health Guardrail outperforms general-purpose LLM safety layers​

A team at Verily published a clinical-grade guardrail for psychiatric crisis detection in text-based conversations, evaluated on two clinician-labeled datasets — the Verily Mental Health Crisis Dataset v1.0 (1,800 simulated messages) and a 794-message subset of the NVIDIA Aegis AI Content Safety Dataset. The Verily Mental Health Guardrail (VMHG) reached sensitivity 0.990 and specificity 0.992 on the Verily dataset (F1 = 0.939; category-level sensitivity 0.917–0.992, specificity ≥ 0.978), and was significantly more sensitive than the NVIDIA and OpenAI guardrails (p < 0.001) at comparable specificity. Inter-rater reliability among the labelling clinicians was extremely high (Cohen's κ = 0.99). The release is the most concrete attempt yet at a purpose-built safety layer for LLM-mediated mental-health conversations rather than relying on general content moderation.

Source: Verily Life Sciences team · npj Digital Medicine · 2026 · 10.1038/s41746-026-02579-5

PsychiatryBench: 5,188-item textbook-grounded multi-task benchmark for psychiatric LLMs​

A new benchmark from a research group publishing in npj Digital Medicine is the first psychiatry-specific evaluation suite curated exclusively from authoritative psychiatric textbooks and casebooks. It comprises eleven distinct question-answering tasks (diagnostic reasoning, treatment planning, longitudinal follow-up, management planning, sequential case analysis, multiple-choice / extended matching) totalling 5,188 expert-annotated items. The authors evaluated frontier models (Google Gemini, DeepSeek, Sonnet 4.5, GPT-5) and leading open medical models (MedGemma) using both conventional metrics and an LLM-as-judge similarity scoring framework. The headline result: substantial gaps in clinical consistency and safety persist in current frontier models, particularly on multi-turn follow-up and management tasks — i.e. precisely the regimes a clinical deployment would inhabit. PsychiatryBench is the first benchmark suitable for tracking psychiatric-domain safety drift across model releases.

Source: PsychiatryBench authors · npj Digital Medicine 9, Article 320 · 2026 · 10.1038/s41746-026-02582-w

---

Wearable Biosensors and Digital Biomarkers​

Oura Ring passive measures associate with next-day panic attacks​

A Frontiers in Digital Health study from a Boston-area group followed 182 young adults — with and without adverse childhood experiences and psychiatric diagnoses — for over six months of continuous Oura Ring passive sensing, and analysed the relationship between ring-derived physiological measures and self-reported panic attacks the following day. Changes in Oura-derived indices were associated with next-day panic attacks, and the associations differed across diagnostic groups. The study is one of the first long-duration passive-sensing analyses to use an event-prediction (not state-classification) framing for panic disorder, and one of the first to stratify the signal by ACE / diagnosis status.

Source: Frontiers in Digital Health · 2026 · 10.3389/fdgth.2026.1764371

First modality-specific translational synthesis of wearable ECG and PPG for anxiety​

A PRISMA-guided systematic review of 38 studies (2015–2025) by Elgendi and colleagues at npj Digital Medicine is described by the authors as the first translational synthesis dedicated specifically to wearable ECG- and PPG-based anxiety detection. The review emphasises that data-driven analytics combined with these signals are now genuinely promising, but cautions that translation into routine care has been slow because of inconsistent recording protocols, mixed reference standards, and limited cross-cohort evidence. This review is the field's new canonical reference for anxiety-specific wearable cardiology, distinct from broader stress / depression literature.

Source: Elgendi M, Elkhalifa A, Alhashmi N, et al. · npj Digital Medicine · 2026 · 10.1038/s41746-026-02620-7

Wearable-AI depression detection: pooled sensitivity 0.89, specificity 0.93 across 16 studies​

A JMIR Mental Health systematic review and meta-analysis aggregated 16 studies (1,189 patients, 13,593 samples) on AI-based depression detection from wearable devices. Pooled sensitivity was 0.89, specificity 0.93, with a diagnostic odds ratio of 110.47. The numbers are headline-friendly but inherit the same caveats as the underlying primary literature — small cohort sizes, mostly within-cohort evaluation, and PHQ-9-style reference standards. Still, this is now the most cited-able single benchmark for "where is wearable depression detection in 2026" and replaces the 2024 numbers most reviews currently quote.

Source: JMIR Mental Health · 2026 · 10.2196/85319

Cross-platform digital biomarkers and anxiety: machine-learning models hit 90.9% with multi-device fusion​

A Journal of Medical Internet Research systematic review and meta-analysis on the association between digital biomarkers of health and anxiety found machine-learning prediction accuracies ranging from 56.3% to 90.9%, with the top-performing models combining data from more than one device class (wrist-worn wearable plus smart shirt). The review's most clinically actionable conclusion is that digital biomarkers function best as inputs alongside self-report and clinical data, not as stand-alone screens.

Source: Journal of Medical Internet Research · 2026 · 10.2196/73812

---

Digital Phenotyping​

School-based smartphone phenotyping in adolescents: feasibility for early risk stratification​

A JMIR feasibility study used the Mindcraft app to combine active self-reports and passive smartphone sensor streams in school-going adolescents, and applied machine learning to predict internalising and externalising difficulties, eating disorders, insomnia, and suicidal ideation. The study's primary contribution is methodological — it demonstrates a low-burden, school-deployed data-collection pattern in a non-clinical adolescent cohort, which is one of the field's harder populations to recruit and retain.

Source: Journal of Medical Internet Research · 2026 · 10.2196/72501

Smartphone-only digital phenotyping: 2012–2025 scoping review​

A second JMIR review provides the first comprehensive synthesis specifically of smartphone-only digital phenotyping studies (i.e. excluding wearable-augmented designs) across mental health, physical health, and substance use. Of the included studies, 45 used smartphone phenotyping for mental-health conditions — the dominant application — confirming that the smartphone-only substrate remains the field's centre of gravity even as wearable fusion grows.

Source: Journal of Medical Internet Research · 2026 · 10.2196/84146

Behapp passive location and app-usage data discriminates depression / anxiety symptoms​

A JMIR Mental Health cross-sectional digital phenotyping study using the Behapp platform to passively track location and app usage across 217 individuals (109 symptomatic for depression / anxiety; 108 asymptomatic) reports that smartphone-tracked behavioural markers carry useful signal for recognising depressive and anxious symptomatology. The study is notable for using the Behapp platform — which has been less visible than Beiwe and mindLAMP in the academic literature to date — and for grounding its labels in self-reported symptoms rather than clinical interview.

Source: JMIR Mental Health · 2026 · 10.2196/80765

---

Multimodal AI Systems​

Emotion-aware social robot pilots conversational depression detection​

A JMIR Formative Research pilot study tested multimodal depression detection through scripted conversational interactions with an emotion-aware social agent. The contribution is a conversational-interaction substrate for multimodal data collection rather than a benchmark — the work proposes the social-robot platform as a more naturalistic alternative to lab-recorded clinical-interview corpora (DAIC-WOZ et al.) for collecting multimodal training data.

Source: JMIR Formative Research · 2026 · 10.2196/84110

---

Ethics, Regulation, and Clinical Translation​

Utah HB 452 gets its first peer-reviewed post-mortem​

A commentary in npj Digital Medicine by Nina de Lacy (University of Utah Huntsman Mental Health Institute) and Zachary Boyd (Utah Office of Artificial Intelligence Policy) walks through the state's pre-deployment regulatory review of mental-health AI agents and how it shaped HB 452 — the nation's first state-level mental-health-chatbot law. HB 452 codifies disclosure-on-first-use and disclosure-after-7-day-gap requirements, third-party data-sharing prohibitions, advertising restrictions, and a "safe harbor" for systems that pre-deploy clearly defined safety guardrails (safety testing, crisis-escalation protocols, clinical oversight, ongoing monitoring). Penalties range up to $2,500 per violation plus injunctive relief. The commentary is the most authoritative public account of what evidence Utah evaluated before legislating, and is likely to become a template reference for other state-level efforts.

Source: de Lacy N, Boyd Z · npj Digital Medicine · 2026 · 10.1038/s41746-026-02580-y

Therapists are starting to ask patients about chatbot use​

WBUR's "AI in the doctor's office" series (5–7 May 2026) reported that mental-health clinicians are increasingly asking patients about generative-AI chatbot use as a routine intake question — a practice in line with the JAMA Psychiatry recommendation that providers treat AI chatbot use as a substance-use-style intake item. WBUR's interactive evaluation of ChatGPT, Claude, and Gemini responses to mental-health prompts, scored by Boston-area therapists, found that the chatbots performed well on validation and empathy but routinely omitted safety steps (escalation recommendations, indication of scope, signposting to professional care). 16% of US adults self-reported using AI tools for mental-health support in the past year.

Source: WBUR · "Many people now trust AI with their feelings…" · 7 May 2026 · wbur.org

LLM-generated psychiatric vignettes: relevance high, safety lower​

A npj Digital Medicine evaluation tested ChatGPT-5 Pro's ability to generate psychiatric vignettes depicting patient chatbot use. Three board-certified psychiatrists scored the vignettes on chatbot relevance, diagnostic sufficiency, explanation quality, and safety. Relevance and diagnostic sufficiency were rated high; safety scored lower. The framing is interesting: as chatbot use itself becomes a clinical phenomenon to teach, the field needs evaluation suites that can audit the teaching artefacts generated by LLMs about chatbot-mediated psychopathology.

Source: npj Digital Medicine · 2026 · 10.1038/s41746-026-02605-6

---

Industry and Product News​

Tava Health closes $40M Series C, launches free AI scribe + practice-management platform​

Tava Health, a hybrid behavioural-health platform, closed a $40M Series C led by Centana Growth Partners and used the round to launch Symphony — a free AI-enabled practice-management bundle for behavioral providers integrating an AI clinical scribe, treatment planning tools, scheduling, and telehealth. The strategic move is to seed the provider workflow surface with a no-cost adoption point and monetise downstream — the same playbook several behavioral-health technology companies are now pursuing post-2025-funding-correction.

Source: MobiHealthNews · May 2026 · mobihealthnews.com

Digital therapeutics market projected at $38.2B by 2030​

A Wissen Research market report (released 7 May 2026) projects the global digital therapeutics market growing from $10.5B in 2025 to $38.2B by 2030 (CAGR 29.4%). Mental-health applications are called out specifically as a high-demand sub-segment.

Source: PR Newswire / Wissen Research · 7 May 2026 · prnewswire.com

---

Forward Outlook​

• Near-term: Expect rapid uptake of PsychiatryBench as a release-time evaluation gate for psychiatric-domain LLM applications, and parallel publication of Anthropic / OpenAI / Google scores against it. The Verily Mental Health Guardrail will likely be benchmarked against by competing safety-layer projects within months.
• Mid-term: The Utah HB 452 commentary will be cited in pending state-level efforts (Colorado, California, New York have adjacent bills in committee) and will likely inform how the FDA's forthcoming digital-mental-health-device guidance treats deployed chatbots vs. medical-device software.
• Long-term: The Oura panic-attack work points toward an emerging event-prediction framing for wearable mental-health analytics — predicting tomorrow's symptom event from today's passive data — which is a more clinically actionable target than the field's traditional cross-sectional state-classification framing.

---

Sources used: 13 · Week 1 · Next issue: 16 May 2026

Weekly Intelligence · BASELINE EDITION · 2 May 2026​

Foundational state-of-the-field report. The dedup baseline against which every weekly issue is measured.

Note on this issue. This is the foundational baseline for the Inflection Weekly series. It maps the field as it stands today — the research streams, datasets, institutions, and open problems. Every subsequent weekly issue will report only what is genuinely new and not already covered here.

---

Executive Summary​

The field of computational behavioral analysis for early identification of mental health conditions has matured from single-modality questionnaire augmentation into a multimodal, sensor-rich, AI-driven discipline. Smartphones, wearables, voice, video, and language models now form a layered stack of passive and active signals that can — under the right conditions — detect depression, anxiety, psychosis, bipolar disorder, and PTSD before clinical deterioration becomes obvious. Reported accuracies are high, but generalisability remains the field's weakest link: most models are trained on small, demographically narrow datasets and degrade sharply when deployed outside their training context. Regulators (FDA, EMA) are catching up — 2025 marked the FDA's first dedicated advisory committee on generative-AI mental-health devices — but no generative AI tool has yet been cleared for psychiatric indication. The commercial landscape is bifurcating: voice-biomarker pioneers (Mindstrong, Kintsugi) have closed or pivoted, while platform-grade digital phenotyping projects (mindLAMP, Beiwe) continue to expand globally. The next 12–24 months will be defined by foundation-model ports into psychiatry, regulatory clarity around model drift, and the first prospective clinical trials of multimodal screening pipelines.

---

1. Introduction & Scope​

"Human behavioral analysis for early identification of mental health conditions" describes the use of objective, machine-readable signals from human behavior — speech, language, facial expression, movement, physiology, smartphone use, social interaction — to identify the early signature of psychiatric conditions before they reach diagnostic threshold or before relapse occurs in a known patient.

The clinical motivation is well-established. Mood, anxiety, and psychotic disorders typically have a prodromal period in which subtle behavioral changes precede full symptom emergence by weeks or months. Standard care relies on infrequent self-report (PHQ-9, GAD-7, PCL-5) administered during clinical visits, which captures a narrow temporal window and is vulnerable to recall bias and social desirability. Behavioral analysis aims to densify and objectify this signal, turning a quarterly snapshot into a continuous longitudinal trace.

This report series covers nine domains: AI/ML model architectures, wearable biosensors, speech and vocal biomarkers, NLP and text-based detection, digital phenotyping, multimodal fusion, facial expression and computer vision, ethics/regulation/clinical translation, and industry/product news. Each weekly issue surfaces only what is new in the prior seven days.

---

2. History and Evolution of the Field​

The pre-history is instrument-based. From the 1960s through the 1990s, psychiatric assessment was dominated by structured interviews (SCID, MINI) and self-report scales (Beck Depression Inventory, Hamilton Rating Scale, PHQ-9). These remain the reference standard against which every computational method is validated, but they are coarse, episodic, and clinician-time-intensive.

The first computational shift came in the 1990s and early 2000s with acoustic analysis of speech in depression — pioneering work by Cummins, Quatieri, and France showed that speakers with depression exhibit reduced pitch variability, longer pauses, and reduced articulatory precision. These findings remain foundational; the difference today is the modeling stack on top of them.

The second shift, roughly 2008–2014, was the smartphone era. The combination of always-on sensors (accelerometer, GPS, microphone, screen events) with always-connected uplink made continuous passive sensing possible at population scale. The term digital phenotyping was introduced by Jukka-Pekka Onnela and Tom Insel in 2016 to describe the moment-by-moment quantification of the individual-level human phenotype using personal digital devices. Open-source research platforms — AWARE (Aalto), Beiwe (Onnela Lab, Harvard), and mindLAMP (Beth Israel Deaconess / Division of Digital Psychiatry) — emerged in this window and now anchor most academic field studies.

The third shift was deep learning, 2015 onward. CNNs on Mel spectrograms, RNN/LSTM models on sequential sensor streams, and later Transformer architectures on multimodal inputs displaced hand-crafted feature pipelines. The AVEC workshop series (2011–2019), built on the DAIC-WOZ corpus, was instrumental in standardising depression-severity benchmarks for this generation of models.

The current shift, beginning around 2022 and accelerating through 2025–2026, is the foundation model era. Self-supervised speech models (wav2vec 2.0, HuBERT, Whisper), large language models (GPT-class, Llama-class, Med-PaLM), and multimodal Transformers are being fine-tuned on clinical corpora. They bring two qualitative changes: (1) far stronger zero- and few-shot performance, softening the field's chronic data-scarcity problem; and (2) a shift in the regulatory question from "can this device be cleared?" to "can this evolving model be cleared and stay cleared?"

---

3. Current Research Streams​

3.1 Wearable biosensors (HRV, EDA, accelerometry)​

Wearables capture three signal families relevant to mental health: cardiovascular (heart rate and heart-rate variability via PPG or ECG), electrodermal (skin conductance), and movement (raw accelerometry, derived sleep and circadian metrics). Heart-rate variability — particularly parasympathetic indices like RMSSD and HF power — is the most consistently validated. Reduced resting HRV has been linked to depression, generalised anxiety, and PTSD across dozens of studies, with autonomic dysregulation as the mechanistic story.

Reported classification accuracies are headline-friendly but should be read with care. Recent machine-learning systems on consumer wearable data report 73–97% accuracy for stress / anxiety / depression states; the higher end typically reflects within-subject prediction on small cohorts rather than cross-subject generalisation. A 2025 systematic review in Sensors fused the wearable literature with AI methods and concluded that the field is moving from feasibility to validation, but that real-world deployment is still bottlenecked by labelling quality and adherence drift (devices removed for charging, showering, or as compliance fades).

Photoplethysmography (PPG) is now the dominant signal in consumer-grade studies because it is present on every smartwatch and most fitness bands. ECG remains the gold standard for HRV but is limited to chest-strap and patch form factors that hurt adherence in non-clinical cohorts.

Key references: Photoplethysmography-based HRV analysis and machine learning for real-time stress quantification (APL Bioengineering, 2025); Fusing Wearable Biosensors with Artificial Intelligence for Mental Health Monitoring: A Systematic Review (Sensors, 2025).

3.2 Speech and vocal biomarkers​

Vocal biomarkers exploit two channels in parallel: the acoustic (pitch, intensity, jitter, shimmer, articulation rate, pause structure, voice quality) and the lexical (word choice, syntactic complexity, sentiment, lexical diversity). Depressive speech tends toward lower pitch, reduced prosodic range, longer and more frequent pauses, and slower articulation. Anxious speech shows higher fundamental frequency variability and faster articulation. Psychotic speech in schizophrenia shows derailment, reduced lexical coherence, and disrupted turn-taking.

The current state of the art combines self-supervised acoustic encoders (wav2vec 2.0, HuBERT) with text encoders fine-tuned on transcripts. The 2025 Voice of Mind model (Deep Learning model for depression and anxiety assessment from acoustic and lexical vocal biomarkers, J. Voice, 2025) exemplifies the hybrid approach: a CNN on Mel spectrograms fused with an MLP integrating lexical features, trained on real-world Italian psychotherapy sessions, generalising across non-pathological voices.

A 2025 J. Voice systematic review on speech and voice quality as digital biomarkers in depression confirmed that the field has moved beyond proof-of-concept but remains divided on methodology — recording protocol (read speech vs. spontaneous vs. clinical interview), cross-language transfer, and clinical reference standard all contribute to between-study heterogeneity. A 2025 BMC Psychiatry meta-analysis on the diagnostic accuracy of traditional and deep-learning methods for speech-based depression detection summarises the same caveat: classification accuracies are promising but cross-cohort generalisation has yet to be demonstrated reliably.

The commercial story is more turbulent. Kintsugi — one of the most-funded voice-biomarker companies — announced in February 2026 that it is winding down commercial operations and releasing its research and technology into the public domain. Ellipsis Health and Sonde Health remain operational, with Ellipsis publishing AI voice biomarker validation work indicating sensitivity 71.3% and specificity 73.5% from as little as 25 seconds of free-form speech for detecting moderate-to-severe depression (JMIR Mental Health, 2025).

3.3 NLP and text analysis (clinical notes, social media, chat)​

Three text sources dominate. Clinical notes in the EHR are the highest-signal corpus but the most access-restricted. NLP on notes is used for cohort identification (suicide-risk flagging, screening for postpartum depression), summarisation of long longitudinal records, and prediction of readmission. Social media text — Reddit (r/SuicideWatch, r/depression), Twitter/X, Facebook — provides scale at the cost of label noise and demographic bias. Direct conversational text from chatbots and therapy apps sits between the two: high context fidelity, smaller but consent-clean cohorts.

LLMs have changed the shape of every category. Recent reviews (a scoping review in JMIR, 2025; a Springer Nature survey on LLMs for mental health diagnosis and treatment, 2025) catalog applications dominated by depression detection (≈35%), clinical treatment support (≈15%), and suicide-risk prediction (≈13%). Performance on benchmark text-classification tasks frequently exceeds non-Transformer baselines, but the published literature is consistent on three failure modes: hallucination, training-data bias (under-representation of marginalised groups, under-detection of risk in those groups), and absence of a benchmarked clinical-ethics framework.

Suicide-ideation detection on social media has converged on Transformer-based ensembles. Reported F1 scores on standard public datasets (SuicideDetection, CEASE v2.0, SWMH) reach 0.97 on the easier sets and 0.75 on harder ones. The headline numbers obscure two persistent issues: demographic underperformance (especially in non-English text and underserved communities) and sharp population-prevalence-driven precision collapse when models trained on balanced research datasets are deployed against the very low base rate of true suicidal crisis in raw feeds.

3.4 Facial expression and affect recognition​

The dominant feature representation is the Facial Action Coding System (FACS). Action units (individual facial muscle movements) are extracted with toolkits such as OpenFace and then fed into temporal models — LSTMs, attention-based recurrent networks, or, increasingly, Transformer encoders over frame sequences. Depression is associated with reduced AU6 (cheek raiser) and AU12 (lip corner puller) activity — i.e. blunted positive affect — while anxiety shows elevated AU12 and AU17 (chin raiser) activity. Recent work reports per-frame depression classification at ≈93% accuracy using AU sequences alone (Big Data and Cognitive Computing, 2024). The SFE-Former architecture (2025) uses a sequential feature collective enhancement unit to capture longer-range temporal dependencies in AU trajectories for depression and anxiety recognition simultaneously.

Limitations are well-rehearsed: lighting and pose sensitivity, demographic bias in face datasets (skin tone, age, gender), and the ethics of camera-on continuous monitoring. The most clinically plausible deployment patterns today are video-call telepsychiatry sessions (consent-clean, controlled lighting) rather than ambient passive monitoring.

3.5 Digital phenotyping (smartphone passive sensing)​

Digital phenotyping fuses the rest of the stack. The standard sensor menu is: GPS (mobility, location entropy, time spent at home), accelerometer (activity, gait, sleep proxy), screen events (use duration, daily and circadian rhythm), call and SMS metadata (sociability, response latency — increasingly hard to access on iOS), and microphone-sampled ambient sound (talk time, speech detection without content). Active components — brief in-app surveys, ecological momentary assessment (EMA) — are layered on top.

Three open platforms anchor the field: Beiwe (Onnela Lab, Harvard), mindLAMP (Division of Digital Psychiatry, Beth Israel Deaconess / McLean Hospital), and AWARE (originally Aalto University). The mindLAMP-anchored LAMP Consortium has grown to 54 sites worldwide. Recent 2025–2026 systematic reviews (JMIR, 2025–2026) catalog rapid expansion: depression is the most frequently studied condition (n≈16 studies), followed by bipolar disorder (n≈11), stress/anxiety (n≈10), and schizophrenia (n≈8). Heart-rate variability, step counts, and speech patterns recur as the most discriminating cross-platform features. Adherence remains the dominant operational constraint: studies routinely lose 30–50% of participants to drop-off within 12 weeks.

3.6 Multimodal AI fusion​

The intuition is straightforward: any single modality is noisy, but the noise is partially independent across modalities, so fusion should improve calibration and robustness. The literature supports the intuition. A 2025 systematic review and meta-analysis on AI-assisted multimodal information for depression screening (PMC, 2025) reports a pooled AUC of 0.95 for multimodal methods, against 0.84–0.92 for unimodal baselines.

Architecturally, Transformer self-attention has become the workhorse: it provides a single mechanism for late, mid, and early fusion across heterogeneous tokenised inputs (audio frames, text tokens, video frames, sensor windows). Recent representative systems include the WACV 2025 Multimodal Interpretable Depression Analysis model (visual + physiological + audio + text), the Integrative Multimodal Depression Detection Network (IMDD-Net) which combines local and global features from video and audio, and a 2025 Frontiers in Psychiatry paper on a video-audio-text deep model achieving pooled sensitivity 0.88 and specificity 0.91. Remote photoplethysmography (rPPG) extracted directly from facial video is increasingly used to add a "free" physiology channel to video-first systems.

The dominant open question is interpretability. Multimodal Transformer outputs are difficult to explain in clinically meaningful terms; current explanation methods (attention visualisation, SHAP, modality ablation) are useful for engineers and unconvincing for clinicians.

3.7 Social media behavioral analysis​

Distinct from the NLP stream above (which treats text as the primary signal), this stream treats behavior on platforms — posting cadence, network position, image content, engagement — as the unit of analysis. The classic body of work is on Facebook and Twitter for depression and on Instagram image filters for depression severity. The current frontier is on short-form video (TikTok, Reels) and on multi-platform fusion. Methodological progress has slowed since the 2018– 2022 platform-API restrictions; what was once an open research substrate is now substantially walled off, pushing the work toward smaller donated-data cohorts and synthetic augmentation.

3.8 Gut-brain axis and biological markers (emerging)​

Not a behavioral signal per se, but an increasingly entangled adjacent layer. The microbiota–gut– brain axis (MGBA) is now an established mechanistic story in depression pathogenesis, with three interconnected pathways: neural signaling (vagal), endocrine (HPA-axis modulation), and immune (systemic inflammation, cytokine signaling). Specific microbial signatures — reduced Faecalibacterium prausnitzii, increased Enterobacteriaceae — recur as candidate diagnostic biomarkers across the 2025 review literature, alongside short-chain fatty acid disturbances and kynurenine-pathway alterations. The reproducibility of these biomarkers across cohorts remains limited, but the mechanistic framework is now stable enough that integrative AI work is starting to fuse microbiome features with behavioral phenotypes.

---

4. Key Research Institutions and Groups​

Academic anchor points (non-exhaustive):

• Division of Digital Psychiatry, Beth Israel Deaconess / McLean Hospital (John Torous and collaborators) — mindLAMP platform, LAMP Consortium, severe-mental-illness deployments.
• Onnela Lab, Harvard T.H. Chan School of Public Health — Beiwe platform, statistical foundations of digital phenotyping, schizophrenia relapse prediction.
• University of Southern California, Institute for Creative Technologies — DAIC-WOZ corpus, the Ellie virtual interviewer.
• MIT Media Lab, Affective Computing group — speech, video, and physiological-signal affective computing; long-running EEG and EDA wearable work.
• Stanford (Calhoun, Williams, Jha collaborations) — neuroimaging-behavior fusion, AI for depression treatment selection.
• Vanderbilt University Medical Center / Colin Walsh — EHR-based suicide-risk prediction.
• University of Cambridge / Sandrine Müller, Andrew Przybylski (Oxford) — ethics and evidence quality in digital phenotyping and screen-time research.
• King's College London, IoPPN — REMOTE-MS, RADAR-CNS programmes for remote assessment of depression, epilepsy, and multiple sclerosis.

Industry actors with active research programmes include Apple (longitudinal Heart and Movement Study cohorts feeding mood research), Google/Verily (Project Baseline), Meta Reality Labs (face and body tracking research), Apple-backed research at the University of California, Los Angeles (UCLA Depression Grand Challenge), and a long tail of voice-biomarker, chatbot, and wearable startups.

---

5. Landmark Datasets and Benchmarks​

• DAIC-WOZ / E-DAIC (USC ICT) — 142 participants in the original, 275 in the extended version, audio + video + transcript with PHQ-8 and PCL-C labels. The default benchmark for multimodal depression severity estimation.
• AVEC challenge series (2011–2019) — annual benchmark and workshop on audio-visual emotion and depression recognition; crystallised the modern evaluation protocols.
• DepAudioNet / EATD-Corpus — Mandarin depression audio for cross-language work.
• Pittsburgh Sleep Quality / Stanford STAGES — sleep-EEG and PSG datasets used as adjacent ground truth for wearable sleep work.
• Reddit Mental Health Dataset / RSDD / SWMH / SuicideDetection — large-scale text corpora for depression and suicidal-ideation classification.
• WESAD — wrist + chest multimodal stress dataset (PPG, EDA, EMG, respiration, ACC) with amusement/stress/baseline labels; the canonical wearable stress benchmark.
• DREAMER / SEED / MAHNOB-HCI — physiological-signal emotion recognition datasets.
• AffectNet / RAF-DB / FER2013 — facial-affect classification datasets, used widely though with documented demographic-bias issues.
• UK Biobank / All of Us — population-scale cohorts with mental-health phenotyping and growing wearable / digital-health linkage; the most plausible substrate for the next generation of generalisable models.

---

6. Conditions Covered by Current Research​

Depression (MDD, persistent depressive disorder). The most-studied condition by a wide margin. Strongest evidence base across speech, text, facial AU, wearable HRV, and digital phenotyping. PHQ-8 / PHQ-9 is the dominant reference standard, which is itself a limitation: classifiers learn to predict the questionnaire, not the underlying state.

Anxiety disorders (GAD, social anxiety, panic). Frequently studied, often as a comorbid label alongside depression. HRV and speech are the strongest individual modalities. Discrimination from depression is non-trivial and a known weak point of single-modality systems.

Schizophrenia and psychosis. Smaller cohorts, but very high-signal modalities: speech coherence and lexical disorganisation, and digital-phenotyping-detected social withdrawal. The Beiwe-anchored relapse-prediction work (Onnela Lab and collaborators) is the canonical example.

Bipolar disorder. Episodic structure makes this the most natural fit for longitudinal passive sensing — mania often shows up first as sleep disruption, increased mobility, and elevated speech rate. mindLAMP and Beiwe deployments dominate the academic literature.

PTSD. Speech (DAIC-WOZ PCL-C labels), HRV, sleep, and facial-affect signals all carry signal. Smaller datasets than depression, and the field is more cautious about deployment because of the veteran-population history and the salience of false positives.

ASD (autism spectrum disorders). Computer vision on social interaction and gaze-pattern analysis dominate. Less overlap with the affective stack.

ADHD. Accelerometry-based activity rhythm analysis, screen-event patterns, and EHR-NLP work; less integration with the affective-modality stack.

Suicidality. Cross-cuts every modality. EHR-based clinical models (Walsh and others) and social-media text models are the two most mature lines.

---

7. Ethical and Regulatory Landscape​

The U.S. FDA's Digital Health Advisory Committee (DHAC) met on 6 November 2025 in a first-of-its- kind review of how generative-AI-enabled digital mental-health devices should be regulated. The public outputs of that meeting — and adjacent FDA materials including the FDA Perspective: Generative Artificial Intelligence-Enabled (GenAI) Digital device note — converged on three themes. One, no generative-AI-based mental-health tool has yet received FDA authorization; the >1,250 AI-enabled medical devices on the public list are non-generative or sit outside psychiatric indications. Two, the FDA is leaning on a predetermined change control plan (PCCP) plus a performance monitoring plan as the primary instruments for managing model drift post-clearance. Three, the agency expects safety-by-design (ISO 14971 risk-management), human-in-the-loop oversight, and transparent labelling of intended use, limitations, model role, data practices, and update policy.

The corresponding academic synthesis (npj Mental Health Research, 2025: "FDA-authorized software as a medical device in mental health: a perspective on evidence, device lineage, and regulatory challenges") catalogues the existing cleared devices, almost all of which are non-generative (rules-based screening apps, prescription digital therapeutics for ADHD or substance use). The gap between the academic literature and the cleared-device registry is wide and is widely acknowledged.

European frameworks (EU AI Act, GDPR, MDR/IVDR) impose stricter pre-market requirements but offer less specific guidance for AI mental-health devices than the FDA's emerging position. The general 2025 picture: regulators are converging faster than they did for prior medical-AI waves, but the clinical evidence base is still thin enough that clearance and adoption are likely to lag the academic literature by 24–48 months.

The non-regulatory ethics surface — informed consent for passive sensing, demographic bias in training data, data-access power asymmetries between platforms and researchers, and the unresolved question of what duty-of-care is triggered when a passive system detects acute risk — remains the field's most uncomfortable open territory.

---

8. Open Research Gaps​

Generalisation across cohorts. The single most repeated finding in 2025 reviews. Models that report 90%+ within-cohort accuracy frequently drop to 60% or worse when deployed against new populations, languages, devices, or clinical contexts.

Demographic bias. Underperformance on under-represented groups (non-English speakers, Black and Brown patients, older adults, people with disabilities) is documented across speech, vision, and text modalities. Mitigation work is active but no canonical solution has emerged.

Adherence and dropout. Real-world digital phenotyping deployments routinely lose 30–50% of participants within three months. This compromises both the data and the equity of the resulting models (those who drop out are not random).

Reference-standard problem. Self-report scales (PHQ, GAD, PCL) are themselves noisy proxies for the underlying condition. Models trained to predict scale scores inherit the noise and the construct ambiguity of the scales.

Interpretability for clinicians. Multimodal Transformer outputs are not yet expressible in the clinical vocabulary that would permit clinician trust and adoption.

Longitudinal validation. Most published models are cross-sectional. The clinically meaningful question — does this signal predict transition to clinical state at the patient level over months — is rarely answered with adequate prospective evidence.

Privacy-preserving learning at scale. Federated learning, differential privacy, and on-device inference are well-developed in the literature but underused in deployed mental-health systems.

Action problem. Detection without an intervention pathway is of limited clinical value. The integration of detection systems with stepped-care escalation, crisis services, and clinician workflow is the under-addressed second half of the field.

---

9. Near-Term Outlook (12–24 months)​

• Foundation-model ports into psychiatry. Expect a wave of papers fine-tuning open-weight speech (Whisper, wav2vec 2.0, SeamlessM4T) and language (Llama-class, open Med-PaLM derivatives) foundation models on clinical mental-health corpora. The combination of better zero-shot baselines and tighter tooling will compress model-development cycles.

• Regulatory consolidation around PCCPs. The FDA's predetermined-change-control-plan framework will become the reference instrument for AI mental-health device clearances. Expect the first generative-AI device authorisation to be a tightly scoped, low-risk indication (administrative or screening, not diagnostic).

• Multimodal fusion as the default. Single-modality publications will continue but the competitive bar for headline papers will move to genuinely multimodal systems with cross-cohort evaluation.

• Wearable platform plays. Apple and Google will continue feeding longitudinal cohort data into mental-health-adjacent research; expect new disease-area-labelled subcohorts within Heart and Movement Study and Project Baseline.

• Industry attrition continues. Following Mindstrong's wind-down and Kintsugi's announced closure, expect further consolidation among voice-biomarker-only companies. Survivors will be those with either platform plays (clinical workflow integration) or enterprise channels (payer / health-system contracts).

• Prospective trials. The first sufficiently powered prospective clinical trials of multimodal digital biomarkers for depression and bipolar relapse should report in this window. Their results — positive or negative — will be the most consequential evidence the field has generated to date.

---

Sources used: 12 · BASELINE EDITION · Next issue: weekly cadence begins with Issue #001